SAFC signs API development deal with Korean firm

Sigma-Aldrich Fine Chemicals (SAFC) has signed an agreement with CrystalGenomics (Seoul) to support the development of active pharmaceutical ingredients (APIs) for next-generation nonsteroidal anti-inflammatory drugs. The agreement represents SAFC’s first pre-formulation services contract into the Korean pharmaceutical market. CrystalGenomics is a clinical stage biopharmaceutical company that is involved in the discovery and development of innovative drugs based on structural chemoproteomics, a technology designed to accelerate drug discovery. The company is...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers